Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02785133 · ClinicalTrials.gov registry record · NA

Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline

A NA study of Fatigue and Quality of Life, sponsored by UVLrx Therapeutics.

Completed
Registry status
NA
Development phase
3,063
Enrollment target
1
Study location

NCT02785133: Completed NA study of Fatigue and Quality of Life, sponsored by UVLrx Therapeutics.

NCT02785133 is a NA study of Fatigue and Quality of Life that has completed, run by UVLrx Therapeutics. The registered enrollment target is 3,063 participants, above the 190-participant average among 109 other Fatigue trials with a reported enrollment target (1512% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02785133, a NA study of Fatigue and Quality of Life, has completed, sponsored by UVLrx Therapeutics.

COMPLETED
Registry status
NA
Development phase
3,063 participants
Enrollment target
1
Study location

Study Summary

This study uses a prospective non-randomized, non-controlled design. Five-hundred (500) subjects having previously received a peripheral intravenous therapy will be enrolled into a single treatment group. The purpose of the study is to evaluate the safety, feasibility, and improved energy levels following treatment with a low-light source integrated into an existing peripheral intravascular catheter. The absence of a control group is based on the following reason:This is a pilot investigation to establish a baseline understanding of the safety, feasibility, and cursory utility of polychromatic light emitting diodes integrated into an existing 20-gauge 1.0 inch intravenous catheter to improve self-reported overall subject energy levels.

Primary Outcome

The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. It has become the world standard method for making this assessment. The Epworth Sleepiness Scale will be used to evaluate subject energy levels at both baseline and post-procedure administration phase. Subjects will rate, on a 4-point scale (0 - 3), their usual chances of dozing off or falling asleep in 8 differe

Conditions Studied

Interventions

  • DEVICE UVL1000 Treatment Station
  • DRUG Normal Saline Solution
  • DEVICE Peripheral Catheterization

Study Locations (1)

Texas

  • Lozano Medical Clinic - Dallas

Trial Details

FieldValue
Enrollment Target 3,063 participants
Start Date 2014-12
Est. Completion 2016-10
Phase NA
UVLrx Therapeutics

1 total trials

What the finished NCT02785133 record still lists

NCT02785133 is an interventional study that assigns participants to a tested intervention. Its 3,063 participants enrollment target places it among the larger protocols in the corpus, above the 190-participant average among 109 other Fatigue trials with a reported enrollment target (1512% higher).

The record links to 2 conditions, with Fatigue appearing as the primary indexed condition, and to 3 interventions - of which UVL1000 Treatment Station is the first listed.

NCT02785133 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02785133 about?

NCT02785133 is a clinical study titled "Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline". This study uses a prospective non-randomized, non-controlled design. Five-hundred (500) subjects having previously received a peripheral intravenous therapy will be enrolled into a single treatment group. The purpose of the study is to evaluate the safety, feasibility, and improved energy levels fol...

What is the current status of trial NCT02785133?

This trial is currently completed. It is a NA study. The enrollment target is 3,063 participants. The study started on 2014-12. Estimated completion is 2016-10.

What conditions does trial NCT02785133 study?

This clinical trial studies the following conditions: Fatigue, Quality of Life.

What interventions are being tested in trial NCT02785133?

The interventions under investigation include: UVL1000 Treatment Station (DEVICE), Normal Saline Solution (DRUG), Peripheral Catheterization (DEVICE).

Who is sponsoring clinical trial NCT02785133?

This trial is sponsored by UVLrx Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02785133 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fatigue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02785133's enrollment target sits among peer trials

3,063 2nd of 109 the highest of 109 other Fatigue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06667700 · 3,082 participants · Phase 3

    A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

  • NCT07116967 · 3,040 participants · Phase 3

    Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  • NCT05534243 · 3,090 participants · NA

    The ED-AWARENESS-2 Trial

  • NCT04722822 · 3,100 participants · NA

    The HPV 9-10 Trial: Early Initiation of HPV Vaccination

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02785133, the US trial registry maintained by the National Library of Medicine. NCT02785133 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.